PDF herunterladen
Notfall & Hausarztmedizin 2009; 35(3): 130-138
DOI: 10.1055/s-0029-1220804
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Vorhofflimmern – Aktuelle Leitlinien – Therapie in der Praxis und Indikation zur Elektrophysiologie

Atrial fibrillation: current guidelines – Therapy in medical practice and indication for electrophysiologyVolker Kühlkamp1
  • 1Abteilung Elektrophysiologie, Herz-Neuro-Zentrum Bodensee, Kreuzlingen (Schweiz) (Chefarzt: Prof. Dr. med. Volker Kühlkamp)
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
14. April 2009 (online)

    Lizenzen und Reprints

Erratum zu diesem Artikel:

ErratumNotfall & Hausarztmedizin 2009; 35(04): 218-218
DOI: 10.1055/s-0029-1222513

Vorhofflimmern ist eine der wesentlichen Ursachen für Morbidität und Mortalität vor allem im höheren Lebensalter. Bei den meisten Patienten ist an erster Stelle die Frage der Antikoagulation zu klären. Aus grundsätzlichen Überlegungen heraus wäre es wünschenswert, den Sinusrhythmus zu erhalten bzw. wieder herzustellen. Medikamente sind jedoch leider zum Erhalt des Sinusrhythmus wenig effektiv. Deutlich wirkungsvoller ist die Katheterablation des Vorhofflimmerns. Die Komplexität und die Risiken des Verfahrens erlauben jedoch keinen breiten Einsatz, zumal wesentliche Fragen – wie zum Beispiel die nach der Antikoagulation nach Katheterablation bei Risikopatienten – noch nicht beantwortet sind.

Atrial fibrillation is one of the essential causes of morbidity and mortality especially in patients of advanced age. In most of the patients it is of primary importance to clarify first of all the problem of anticoagulation. Fundamentally, it would be desirable to maintain or re-establish the sinus rhythm. Unfortunately, however, drugs are not very effective in maintaining the sinus rhythm. Catheter ablation of the atrial fibrillation is definitely more effective. This is however a complicated and risky procedure, so that it cannot be done on a large scale, the more so since essential questions are still unanswered, such as anticoagulation after catheter ablation in risk patients.

Key words

atrial fibrillation - anticoagulation - rate control - rhythm control - sinus rhythm - catheter ablation

Literatur

  • 1 Benjamin EJ, Wolf PA, D'Agostino RB. et al. . Impact of atrial fibrillation on the risk of death: the Framingham Heart Study.  Circulation. 1998;  98 946-952
    CrossrefPubMedSuche in Google Scholar
  • 2 Kannel WB, Abbott RD, Savage DD. et al. . Epidemiologic features of chronic atrial fibrillation: The Framingham study.  N Engl J Med. 1982;  306 1018-1022
    CrossrefPubMedSuche in Google Scholar
  • 3 Lloyd-Jones DM, Wang TJ, Leip EP. et al. . Lifetime risk for development of atrial fibrillation. The Framingham Heart Study.  Circulation. 2004;  110 1042-1046
    CrossrefPubMedSuche in Google Scholar
  • 4 Miyasaka Y, Barnes ME, Gersh BJ. et al. . Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.  Circulation. 2006;  114 119-125
    CrossrefPubMedSuche in Google Scholar
  • 5 Stewart S, MacIntyre K, MacLeod MM. et al. . Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986–1996.  Eur Heart J. 2001;  22 693-701
    CrossrefPubMedSuche in Google Scholar
  • 6 Wang TJ, Parise H, Levy D. et al. . Obesity and the risk of new-onset atrial fibrillation.  JAMA. 2004;  24 2471-2477
    PubMedSuche in Google Scholar
  • 7 Wolf PA, Abbott RD, Kannel WB.. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.  Stroke. 1991;  22 983-988
    CrossrefPubMedSuche in Google Scholar
  • 8 Scherf D, Blumenfeld S, Gurbuzer B. et al. . Effect of hypercapnia on aconitine-induced atrial fibrillation and on ventricular fibrillation caused by focal cooling of the rapidly beating ventricles of the dog.  Am Heart J. 1958;  55 733-738
    CrossrefPubMedSuche in Google Scholar
  • 9 Haissaguerre M, Jais P, Shah DC. et al. . Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins.  N Engl J Med. 1998;  339 659-666
    CrossrefPubMedSuche in Google Scholar
  • 10 Moe GK, Abildskov JA.. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge.  Am Heart J. 1959;  58 59-70
    CrossrefPubMedSuche in Google Scholar
  • 11 Wijffels MCEF, Kirchhof CJHJ, Dorland R. et al. . Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats.  Circulation. 1995;  92 1954-1968
    CrossrefPubMedSuche in Google Scholar
  • 12 Nattel S.. New ideas about atrial fibrillation 50 years on.  Nature. 2002;  415 219-226
    CrossrefPubMedSuche in Google Scholar
  • 13 Bosch RF, Zeng X, Grammer JB. et al. . Ionic mechanisms of electrical remodeling in human atrial fibrillation.  Cardiovasc Res. 1999;  44 121-131
    CrossrefPubMedSuche in Google Scholar
  • 14 Fuster V, Ryden LE, Cannom DS. et al. . ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society.  Circulation. 2006;  114
    PubMedSuche in Google Scholar
  • 15 Healey JS, Baranchuk A, Crystal E. et al. . Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.  J Am Coll Cardiol. 2005;  45 1832-1839
    CrossrefPubMedSuche in Google Scholar
  • 16 L'Allier PL, Ducharme A, Keller PF. et al. . Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.  J Am Coll Cardiol. 2004;  44 159-164
    CrossrefPubMedSuche in Google Scholar
  • 17 Siu CW, Lau CP, Tse HF.. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion.  Am J Cardiol. 2003;  9 1343-1345
    PubMedSuche in Google Scholar
  • 18 Young-Xu Y, Jabbour S, Goldberg R. et al. . Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.  Am J Cardiol. 2003;  92 1379-1383
    CrossrefPubMedSuche in Google Scholar
  • 19 Psaty BM, Manolio TA, Kuller LH. et al. . Incidence of and risk factors for atrial fibrillation in older adults.  Circulation. 1997;  96 2455-2461
    PubMedSuche in Google Scholar
  • 20 Kühlkamp V, Bosch RF, Mewis C. et al. . Use of beta-blockers in atrial fibrillation.  Am J Cardiovasc Drugs. 2002;  2 37-42
    CrossrefPubMedSuche in Google Scholar
  • 21 Salem DN, Stein PD, Al-Ahmad A. et al. . Antithrombotic therapy in valvular heart disease – native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.  Chest. 2004;  126
    PubMedSuche in Google Scholar
  • 22 Brass LM, Krumholz HM, Scinto JM. et al. . Warfarin use among patients with atrial fibrillation.  Stroke. 1997;  28 2382-2389
    PubMedSuche in Google Scholar
  • 23 Cohen N, Almoznino-Sarafian D, Alon I. et al. . Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission.  Stroke. 2000;  31 1217-1222
    PubMedSuche in Google Scholar
  • 24 Kalra L, Yu G, Perez I. et al. . Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness.  BMJ. 2000;  320 1236-1239
    CrossrefPubMedSuche in Google Scholar
  • 25 Mant J, Hobbs R, Fletcher K. et al. . Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial.  Lancet. 2007;  370 493-503
    CrossrefPubMedSuche in Google Scholar
  • 26 Benavente O, Hart R, Koudstaal P. et al. .Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2000
    Suche in Google Scholar
  • 27 Hart RG, Halperin JL, McBride R. et al. . Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses.  Arch Neurol. 2000;  57 326-332
    CrossrefPubMedSuche in Google Scholar
  • 28 Hart RG, Benavente O, McBride R. et al. . Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis.  Ann Intern Med. 1999;  131 492-501
    PubMedSuche in Google Scholar
  • 29 Go AS, Hylek EM, Chang Y. et al. . Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?.  JAMA. 2003;  290 2685-2692
    CrossrefPubMedSuche in Google Scholar
  • 30 Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group [see comments].  Lancet. 1993;  342 1255-1262
    PubMedSuche in Google Scholar
  • 31 Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators.  Ann Intern Med. 1992;  116 1-5
    PubMedSuche in Google Scholar
  • 32 Moulton AW, Singer DE, Haas JS.. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study.  Am J Med. 1991;  91 156-161
    CrossrefPubMedSuche in Google Scholar
  • 33 Boysen G, Nyboe J, Appleyard M. et al. . Stroke incidence and risk factors for stroke in Copenhagen, Denmark.  Stroke. 1988;  19 1345-1353
    PubMedSuche in Google Scholar
  • 34 Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators.  JAMA. 1998;  279 1273-1277
    CrossrefPubMedSuche in Google Scholar
  • 35 Pengo V, Legnani C, Noventa F. et al. . Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study.  Thromb Haemost. 2001;  85 418-422
    PubMedSuche in Google Scholar
  • 36 Howard PA, Ellerbeck EF, Engelman KK. et al. . Warfarin for stroke prevention in octogenarians with atrial fibrillation.  Am J Geriatr Cardiol. 2001;  10 139-144
    CrossrefPubMedSuche in Google Scholar
  • 37 Gorter JW.. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups.  Neurology. 1999;  53 1319-1327
    CrossrefPubMedSuche in Google Scholar
  • 38 Hylek EM, Skates SJ, Sheehan MA. et al. . An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation.  N Engl J Med. 1996;  335 540-546
    CrossrefPubMedSuche in Google Scholar
  • 39 Shireman TI, Howard PA, Kresowik TF. et al. . Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients.  Stroke. 2004;  35 2362-2367
    CrossrefPubMedSuche in Google Scholar
  • 40 Gage BF, Waterman AD, Shannon W. et al. . Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.  JAMA. 2001;  285 2864-2870
    CrossrefPubMedSuche in Google Scholar
  • 41 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.  Arch Intern Med. 1994;  154 1449-1457
    CrossrefPubMedSuche in Google Scholar
  • 42 Hohnloser SH, Kuck KH, Lilienthal J.. Rhythm or rate control in atrial fibrillation – Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.  Lancet. 2000;  356 1789-1794
    Suche in Google Scholar
  • 43 Wyse DG, Waldo AL, DiMarco JP, Domanski MJ. et al. . A comparison of rate control and rhythm control in patients with atrial fibrillation.  N Engl J Med. 2002;  347 1825-1833
    CrossrefPubMedSuche in Google Scholar
  • 44 Van Gelder IC, Hagens VE, Bosker HA. et al. . A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.  N Engl J Med. 2002;  347 1834-1840
    CrossrefPubMedSuche in Google Scholar
  • 45 Carlsson J, Miketic S, Windeler J. et al. . Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.  J Am Coll Cardiol. 2003;  41 1690-1696
    CrossrefPubMedSuche in Google Scholar
  • 46 Opolski G, Torbicki A, Kosior DA. et al. . Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study.  Chest. 2004;  126 476-486
    CrossrefPubMedSuche in Google Scholar
  • 47 Steinberg JS, Sadaniantz A, Kron J. et al. . Analysis of cause-specific mortality in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) Study.  Circulation. 2004;  109 1973-1980
    CrossrefPubMedSuche in Google Scholar
  • 48 Pritchett EL, Page RL, Connolly SJ. et al. . Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.  J Am Coll Cardiol. 2000;  36 794-802
    CrossrefPubMedSuche in Google Scholar
  • 49 Singh BN, Connolly SJ, Crijns HJGM. et al. . Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.  N Engl J Med. 2007;  357 987-999
    CrossrefPubMedSuche in Google Scholar
  • 50 Rawles JM.. What is meant by a „controlled“ ventricular rate in atrial fibrillation?.  Br Heart J. 1990;  63 157-161
    CrossrefPubMedSuche in Google Scholar
  • 51 Atwood JE, Sullivan MJ, Forbes SM. et al. . Effect of beta-adrenergic blockade on exercise performance in patiens with chronic atrial fibrillation.  J Am Coll Cardiol. 1987;  10 314-320
    PubMedSuche in Google Scholar
  • 52 Farshi R, Kistner D, Sarma JS. et al. . Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens.  J Am Coll Cardiol. 1999;  33 304-310
    CrossrefPubMedSuche in Google Scholar
  • 53 DiBianco R, Morganroth J, Freitag JA. et al. . Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin.  Am Heart J. 1984;  108 1121-1127
    CrossrefPubMedSuche in Google Scholar
  • 54 Koh KK, Kwon KS, Park HB. et al. . Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation.  Am J Cardiol. 1995;  75 88-90
    CrossrefPubMedSuche in Google Scholar
  • 55 Lundström T, Ryden L.. Ventricular rate control and exercise performance in chronic atrial fibrillation: Effects of diltiazem and verapamil.  J Am Coll Cardiol. 1990;  16 86-90
    PubMedSuche in Google Scholar
  • 56 Lewis R, Lakhani M, Moreland TA. et al. . A comparison of verapamil and digoxin in the treatment of atrial fibrillation.  Eur Heart J. 1987;  8 148-153
    PubMedSuche in Google Scholar
  • 57 Atwood JE, Myers JN, Sullivan MJ. et al. . Diltiazem and exercise performance in patients with chronic atrial fibrillation.  Chest. 1988;  9 20-25
    PubMedSuche in Google Scholar
  • 58 Hnatkova K, Murgatroyd FD, Poloniecki J. et al. . Mid- and long-term similarity of ventricular response to paroxysmal atrial fibrillation: digoxin versus placebo.  Pacing Clin Electrophysiol. 1998;  21 1735-1740
    CrossrefPubMedSuche in Google Scholar
  • 59 Brignole M, Menozzi C, Gianfranchi L. et al. . Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study.  Circulation. 1998;  98 953-960
    CrossrefPubMedSuche in Google Scholar
  • 60 Wood MA, Brown-Mahoney C, Kay GN. et al. . Clinical outcomes after ablation and pacing therapy for atrial fibrillation : a meta-analysis.  Circulation. 2000;  101 1138-1144
    CrossrefPubMedSuche in Google Scholar
  • 61 Doshi RN, Daoud EG, Fellows C. et al. . Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (The PAVE Study).  J Cardiovasc Electrophysiol. 2005;  16 1160-1165
    CrossrefPubMedSuche in Google Scholar
  • 62 Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction.  N Engl J Med. 1989;  321 406-412
    CrossrefPubMedSuche in Google Scholar
  • 63 Waldo AL, Camm AJ, de H Ryuter. et al. . Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction.  Lancet. 1996;  348 7-12
    CrossrefPubMedSuche in Google Scholar
  • 64 Coplen SE, Antman EM, Berlin JA. et al. . Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.  Circulation. 1990;  82 1106-1116
    CrossrefPubMedSuche in Google Scholar
  • 65 Flaker GC, Blackshear JL, McBride R. et al. . Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation.  J Am Coll Cardiol. 1992;  20 527-532
    PubMedSuche in Google Scholar
  • 66 Kühlkamp V, Schirdewan A, Stangl K. et al. . Use of Metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation. A randomized double blind placebo controlled study.  J Am Coll Cardiol. 2000;  36 139-146
    CrossrefPubMedSuche in Google Scholar
  • 67 Plewan A, Lehman G, Ndrepepa G. et al. . Maintenance of sinus rhythm after cardioversion of atrial fibrillation: sotalol vs. bisoprolol.  Eur Heart J. 2001;  22 1504-1510
    CrossrefPubMedSuche in Google Scholar
  • 68 Graboys TB, Podrid PJ, Lown B.. Efficacy of amiodarone for refractory supraventricular tachyarrhythmias.  Am Heart J. 1983;  106 870-876
    CrossrefPubMedSuche in Google Scholar
  • 69 Fetsch T, Breithardt G, Engberding R. et al. . Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.  Eur Heart J. 2004;  25 1385-1394
    CrossrefPubMedSuche in Google Scholar
  • 70 Patten M, Maas R, Bauer P. et al. . Suppression of paroxysmal atrial tachyarrhythmias – results of the SOPAT trial.  Eur Heart J. 2004;  25 1395-1404
    CrossrefPubMedSuche in Google Scholar
  • 71 A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.  Circulation. 1995;  92 2550-2557
    PubMedSuche in Google Scholar
  • 72 Fetsch T, Bauer P, Engberding R. et al. . Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial.  Eur Heart J. 2004;  25 1385-1394
    CrossrefPubMedSuche in Google Scholar
  • 73 Pritchett ELC, Wilkinson WE.. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.  Am J Cardiol. 1991;  67 976-980
    CrossrefPubMedSuche in Google Scholar
  • 74 Alboni P, Botto GL, Baldi N. et al. . Outpatient treatment of recent onset atrial fibrillation with the „Pill-in-the-Pocket“ approach.  N Engl J Med. 2004;  351 2384-2391
    CrossrefPubMedSuche in Google Scholar
  • 75 Pappone C, Rosanio S, Augello G. et al. . Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study.  J Am Coll Cardiol. 2003;  42 185-197
    CrossrefPubMedSuche in Google Scholar
  • 76 Oral H, Chugh A, Ozaydin M. et al. . Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation.  Circulation. 2006;  114 759-765
    CrossrefPubMedSuche in Google Scholar
  • 77 Agnelli G, Gallus A, Goldhaber SZ. et al. . Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): The ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59–7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) Study.  Circulation. 2007;  116 180-187
    CrossrefPubMedSuche in Google Scholar
  • 78 Pappone C, Augello G, Sala S. et al. . A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: The APAF Study.  J Am Coll Cardiol. 2006;  48 2340-2347
    CrossrefPubMedSuche in Google Scholar
  • 79 Oral H, Pappone C, Chugh A. et al. . Circumferential pulmonary-vein ablation for chronic atrial fibrillation.  N Engl J Med. 2006;  354 934-941
    CrossrefPubMedSuche in Google Scholar
  • 80 Wazni OM, Marrouche NF, Martin DO. et al. . Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial.  JAMA. 2005;  293 2634-2640
    CrossrefPubMedSuche in Google Scholar
  • 81 Haissaguerre M, Shah DC, Jais P. et al. . Electrophysiological breakthroughs from the left atrium to the pulmonary veins.  Circulation. 2000;  102 2463-2465
    Suche in Google Scholar
  • 82 Pappone C, Rosanio S, Oreto G. et al. . Circumferential radiofrequency ablation of pulmonary vein ostia: a new anatomic approach for curing atrial fibrillation.  Circulation. 2000;  102 2619-2628
    Suche in Google Scholar
  • 83 Ouyang F, Bansch D, Ernst S. et al. . Complete isolation of left atrium surrounding the pulmonary veins: new insights from the double-lasso technique in paroxysmal atrial fibrillation.  Circulation. 2004;  110 2090-2096
    CrossrefPubMedSuche in Google Scholar
  • 84 Nademanee K, McKenzie J, Kosar E. et al. . A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate.  J Am Coll Cardiol. 2004;  43 2054-2056
    CrossrefPubMedSuche in Google Scholar
  • 85 Haissaguerre M, Jais P, Shah DC. et al. . Right and left atrial radiofrequency catheter therapy of paroxysmal atrial fibrillation.  J Cardiovasc Electrophysiol. 1996;  7 1132-1144
    PubMedSuche in Google Scholar
  • 86 Pappone C, Santinelli V, Manguso F. et al. . Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation.  Circulation. 2004;  109 327-334
    CrossrefPubMedSuche in Google Scholar
  • 87 Scherlag BJ, Yamanashi W, Patel U. et al. . Autonomically induced conversion of pulmonary vein focal firing into atrial fibrillation.  J Am Coll Cardiol. 2005;  45 1878-1886
    CrossrefPubMedSuche in Google Scholar
  • 88 Scherlag BJ, Po S.. The intrinsic cardiac nervous system and atrial fibrillation.  Curr Opin Cardiol. 2006;  21 51-54
    PubMedSuche in Google Scholar
  • 89 Hocini M, Sanders P, Jais P. et al. . Techniques for curative treatment of atrial fibrillation.  J Cardiovasc Electrophysiol. 2004;  15 1467-1471
    CrossrefPubMedSuche in Google Scholar
  • 90 Cappato R, Calkins H, Chen SA. et al. . Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation.  Circulation. 2005;  111 1100-1105
    CrossrefPubMedSuche in Google Scholar
  • 91 Keane D, Reddy V, Ruskin J.. Emerging concepts on catheter ablation of atrial fibrillation from the Tenth Annual Boston Atrial Fibrillation Symposium.  J Cardiovasc Electrophysiol. 2005;  16 1025-1028
    CrossrefPubMedSuche in Google Scholar
  • 92 Raviele A, Themistoclakis S, Rossillo A. et al. . Iatrogenic postatrial fibrillation ablation left atrial tachycardia/flutter: how to prevent and treat it?.  J Cardiovasc Electrophysiol. 2005;  16 298-301
    CrossrefPubMedSuche in Google Scholar
  • 93 Ernst S, Schluter M, Ouyang F. et al. . Modification of the substrate for maintenance of idiopathic human atrial fibrillation: efficacy of radiofrequency ablation using nonfluoroscopic catheter guidance.  Circulation. 1999;  100 2085-2092
    PubMedSuche in Google Scholar
  • 94 O'Neill MD, Jais P, Takahashi Y. et al. . The stepwise ablation approach for chronic atrial fibrillation – evidence for a cumulative effect.  J Intervent Cardiac Electrophysiol. 2006;  16 153-167
    PubMedSuche in Google Scholar
  • 95 Oral H, Knight BP, Ozaydin M. et al. . Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation.  J Am Coll Cardiol. 2002;  40 100-104
    CrossrefPubMedSuche in Google Scholar
  • 96 Hsu LF, Jais P, Sanders P. et al. . Catheter ablation for atrial fibrillation in congestive heart failure.  N Engl J Med. 2004;  351 2373-2383
    CrossrefPubMedSuche in Google Scholar
  • 97 Perisinakis K, Damilakis J, Theocharopoulos N. et al. . Accurate assessment of patient effective radiation dose and associated detriment risk from radiofrequency catheter ablation procedures.  Circulation. 2001;  104 58-62
    CrossrefPubMedSuche in Google Scholar
  • 98 Einstein AJ, Henzlova MJ, Rajagopalan S.. Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography.  JAMA. 2007;  298 317-323
    CrossrefPubMedSuche in Google Scholar
  • 99 Pappone C, Oral H, Santinelli V. et al. . Atrio-esophageal fistula as a complication of percutaneous transcatheter ablation of atrial fibrillation.  Circulation. 2004;  109 2724-2726
    Suche in Google Scholar
  • 100 Cummings JE, Schweikert RA, Saliba WI. et al. . Brief communication: atrial-esophageal fistulas after radiofrequency ablation.  Ann Intern Med. 2006;  144 572-574
    CrossrefPubMedSuche in Google Scholar

1 C = Congestive Heart Failure (Herzinsuffizienz); H = Hypertonie, arterieller Bluthochdruck; A = Alter; D = Diabetes mellitus; S = Schlaganfall

2 Atrial Fibrillation Follow-up Investigation of Rhythm Management

Korrespondenz

Volker Kühlkamp

Herz-Zentrum-Bodensee

Weinbergstraße 1

CH-8280 Kreuzlingen

eMail: volker.kuehlkamp@herz-zentrum.com